TipRanks on MSN

GenFleet Therapeutics launches pioneering Phase III study for pancreatic cancer treatment

Genfleet Therapeutics (Shanghai), Inc. Class H ( (HK:2595) ) just unveiled an announcement.

KRAS-mutant cancers: Potential target could overcome treatment resistance

Researchers at The University of Texas MD Anderson Cancer Center have identified a specific protein, RASH3D19, that is ...